A share price of Arcus Biosciences Inc [RCUS] is currently trading at $24.56, up 8.00%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RCUS shares have gain 5.86% over the last week, with a monthly amount glided 14.07%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on January 13, 2026, when Goldman upgraded its rating to a Buy but kept the price target unchanged to $28 for it. Previously, Morgan Stanley downgraded its rating to Equal-Weight on January 08, 2026, and kept the price target unchanged to $20. On February 26, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $24 on the stock. H.C. Wainwright started tracking the stock assigning a Neutral rating and suggested a price target of $20 on October 21, 2024. Wells Fargo initiated its recommendation with an Overweight and recommended $29 as its price target on October 08, 2024. BofA Securities started tracking with a Neutral rating for this stock on November 18, 2022, and assigned it a price target of $33. In a note dated October 11, 2022, Morgan Stanley initiated an Overweight rating and provided a target price of $40 on this stock.
Arcus Biosciences Inc experienced fluctuations in its stock price throughout the past year between $6.50 and $26.40. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $24.56 at the most recent close of the market. An investor can expect a potential return of 18.08% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
Trailing Twelve Months sales for Arcus Biosciences Inc [NYSE:RCUS] were 240.00M which represents -45.83% decline. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -1.56%, Pretax Profit Margin comes in at -1.45%, and Net Profit Margin reading is -1.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.7 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcus Biosciences Inc [NYSE:RCUS] is 3.65. Further, the Quick Ratio stands at 3.65, while the Cash Ratio is 1.01. Considering the valuation of this stock, the price to sales ratio is 12.66, the price to book ratio is 6.03.
Transactions by insiders
Recent insider trading involved Jaen Juan C., President, that happened on Jan 05 ’26 when 31823.0 shares were sold. Officer, Juan Jaen completed a deal on Jan 05 ’26 to buy 31823.0 shares. Meanwhile, Chief Financial Officer Goeltz II Robert C. sold 6552.0 shares on Dec 31 ’25.
